{
    "clinical_study": {
        "@rank": "18162", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Treatment guided by the gene expression profiles obtained from the CTC"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the feasibility of selecting personalized therapies\n      for colon cancer patients who have failed standard treatments, using a new methodology based\n      on the determination of a profile of chemosensitivity by comprehensive genetic expression\n      analysis from tumor samples."
        }, 
        "brief_title": "Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adenocarcinoma of Colon", 
            "Adenocarcinoma of Rectum", 
            "Metastatic Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma", 
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis", 
                "Rectal Neoplasms", 
                "Colonic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is a prospective, randomized study in patients with metastatic colorectal carcinoma\n      progressing after two lines of prior therapy. Patients will be randomized (1:1) to receive\n      chemotherapy as determined by its oncologist or treatment according to chemosensitivity\n      profile obtained. For obtaining the profile a histological tumor sample and a sample of\n      venous blood in a tube with heparin standard are necessary  . This latter sample will be\n      processed to isolate circulating tumor cells by cell adhesion with matrix coated glass\n      spheres. The RNA from these  circulating  tumor cells as well as  from tumor cells  of tumor\n      biopsies from the same patients will be extracted by a standard procedure for extracting RNA\n      for genetic expression analysis. Based on the analysis performed on tumor biopsy is\n      generated a ranked list of potentially more effective treatments in every case"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological examination showed of metastatic colon carcinoma.\n\n          -  Patients more than 18 years.\n\n          -  Measurable disease according to RECIST 1.1 criteriso\n\n          -  Life expectancymore than 3 months according to the criteria of the investigator.\n\n          -  Goodoverall condition determined by the ECOG scale (score 0-1)\n\n          -  Candidate for systemic treatment based on the profile of sensibility to drugs\n             determined by genetic analysis of the tumor sample. Patients should have received at\n             least two lines of standard treatment, including therapies antiEGFR in cases of\n             tumors with Kras oncogene B-Raf and native (non-mutated).\n\n          -  Availability of tumor tissue or potential for tumor biopsy correlation allowing the\n             RNA expression profile with that obtained from the peripheral blood CTCs.\n\n          -  Adequate hematologic function: ANCmore than 1.5 x 103 / L, platelet count absolute\n             more than 100 x 109 / L, normal values \u200b\u200bof INR and PTT.\n\n          -  Adequate liver function: total serum bilirubin no more than 2 mg / dL, ALT and AST no\n             more than 3 times the upper limit established by the laboratory (LSR) or no more than\n             5 LSR in patients with liver metastases.\n\n          -  Adequate renal function: serum creatinine no more than 1.5 LSR or  calculated\n             creatinine clearance 60 ml / min (Crock).\n\n        Exclusion Criteria:\n\n          -  The patient has received systemic cancer treatment within two weeks prior to\n             extraction of the blood sample.\n\n          -  Patient has received therapeutic radioisotopes such as strontium 89  within 4 weeks\n             before blood extraction.\n\n          -  Patient has had major surgery or percutaneous procedures such as placement of central\n             venous catheter within  2 weeks prior to the blood draw.\n\n          -  Patient has a history as bone marrow transplantation and / or stem cell\n             transplantation.\n\n          -  Patient has any of the following concomitant diseases or current conditions:\n\n        chronic active liver disease of any origin, and / or cirrhosis with Child-Pugh score B or\n        C.\n\n        Uncontrolled active infection. carries the human immunodeficiency virus (HIV). Any other\n        significant disease that in the opinion of the investigator, substantially increase the\n        risk associated with patient participation in this study.\n\n        documented symptomatic brain metastases, progression or requiring corticosteroids or\n        associated to a leptomeningeal involvement.\n\n        Patients with uncontrolled systemic diseases. Patients with Hypertension or  Diabetes\n        Mellitus is countable if at the time of inclusion deemed medically controlled.\n\n        Patients with inability for oral drug delivery, either by preventing gastrointestinal\n        administration situation or severe impairment of intestinal absorption\n\n          -  Any medical or psychiatric condition that, in the opinion of the investigator, may\n             limit the patient's ability to understand and fulfill all requirements under its\n             partcipaci\u00f3n in the study.\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "76 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703910", 
            "org_study_id": "CNIO-GI-01-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "intervention_name": "Arm A chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Capecitabine", 
                    "Cisplatin", 
                    "Cetuximab", 
                    "Doxorubicin", 
                    "Fluorouracil", 
                    "Gemcitabine", 
                    "Irinotecan", 
                    "Topotecan", 
                    "Mitomycin C", 
                    "Oxaliplatin", 
                    "Paclitaxel", 
                    "Docetaxel", 
                    "Pemetrexed", 
                    "Raltitrexed", 
                    "Sorafenib", 
                    "Erlotinib", 
                    "Vinorelbine", 
                    "Dasatinib", 
                    "Etoposide"
                ]
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "arm B chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Capecitabine", 
                    "Cisplatin", 
                    "Cetuximab", 
                    "Doxorubicin", 
                    "Fluorouracil", 
                    "Gemcitabine", 
                    "Irinotecan", 
                    "Topotecan", 
                    "Mitomycin C", 
                    "Oxaliplatin", 
                    "Paclitaxel", 
                    "Docetaxel", 
                    "Pemetrexed", 
                    "Raltitrexed", 
                    "Sorafenib", 
                    "Erlotinib", 
                    "Vinorelbine", 
                    "Dasatinib", 
                    "Etoposide"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mitomycins", 
                "Mitomycin", 
                "Doxorubicin", 
                "Gemcitabine", 
                "Oxaliplatin", 
                "Vinorelbine", 
                "Irinotecan", 
                "Raltitrexed", 
                "Docetaxel", 
                "Pemetrexed", 
                "Capecitabine", 
                "Cetuximab", 
                "Sorafenib", 
                "Cisplatin", 
                "Etoposide", 
                "Fluorouracil", 
                "Paclitaxel", 
                "Topotecan", 
                "Erlotinib", 
                "Dasatinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Genomic expression profile in tumor samples", 
            "Adult patients", 
            "metastatic disease status and progression after two lines of systemic therapy"
        ], 
        "lastchanged_date": "January 21, 2013", 
        "location": [
            {
                "contact": {
                    "email": "alopeza@cnio.es", 
                    "last_name": "Antonio L\u00f3pez, Biologist", 
                    "phone": "91 600 60 28"
                }, 
                "contact_backup": {
                    "email": "lledesma@ext.cnio.es", 
                    "last_name": "Laura Ledesma, Nurse, Study Coordinator", 
                    "phone": "91 600 65 84"
                }, 
                "facility": {
                    "address": {
                        "city": "Fuenlabrada", 
                        "country": "Spain", 
                        "state": "Madrid", 
                        "zip": "28950"
                    }, 
                    "name": "Hospital Universitario de Fuenlabrada"
                }, 
                "investigator": [
                    {
                        "last_name": "Carlos G\u00f3mez, MD., PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Elena Garralda, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ignacio Juez, M.D., PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Manuel Hidalgo, M.D.,Ph.D", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gsanchez@fundacionhm.com", 
                    "last_name": "Gemma S\u00e1nchez, Study Coordinator", 
                    "phone": "(+34) 91 756 79 84"
                }, 
                "contact_backup": {
                    "email": "fatimasolis@hospitaldemadrid.com", 
                    "last_name": "F\u00e1tima Sol\u00eds, Data Manager", 
                    "phone": "(+34) 91 756 79 84"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Hospital Madrid Norte Sanchinarro"
                }, 
                "investigator": [
                    {
                        "last_name": "Antonio Cubillo, M.D.,Ph.D", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jes\u00fas Rodr\u00edguez, M.D., Ph.D", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples.", 
        "overall_contact": {
            "email": "alopeza@cnio.es", 
            "last_name": "Antonio L\u00f3pez, Biologist", 
            "phone": "91 600 60 28"
        }, 
        "overall_contact_backup": {
            "email": "lledesma@ext.cnio.es", 
            "last_name": "Laura Ledesma, Nurse, Study Coordinator", 
            "phone": "91 600 65 84"
        }, 
        "overall_official": {
            "affiliation": "Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO)", 
            "last_name": "Carlos G\u00f3mez, M.D.,Ph.D", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the tumor progression-free survival at 3 and 6 months (PFS3 and PFS6) in both groups of patients and identify whether there is a statistically significant difference", 
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Assess the correlation between the gene expression profiles obtained from the CTC and the gene expression profiles obtained from tumor samples from the same patients.", 
                "measure": "gene expression profiles", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703910"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Centro Nacional de Investigaciones Oncologicas CARLOS III", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Hospital Universitario de Fuenlabrada", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Grupo Hospital de Madrid", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "\u00c1pices Soluciones S.L.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Centro Nacional de Investigaciones Oncologicas CARLOS III", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2012"
    }
}